Advanced Search:
Equity Index

PHARM.AS - PHARMING GROUP

€0.89  0.0185 (2.12%)

Updated: 07:01 May 12, 2024 EST

Next Session's AI Forecast

38.42%

Avg. Accuracy (AI)

€0.51

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€0.84

PHARMING GROUP's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

PHARMING GROUP - HISTORICAL DATA 6M

  • Last price

    €0.89

  • Daily change

    €0.0185

  • Previous Close

    €0.873

  • Last Updated

    07:01 May 12, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-0.51 -0.74 -0.31 -0.15 -0.1

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.03 1.9 1.49 1.46 1.48

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
40.91% 33.33% 11.72% 6.7%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

PHARMING GROUP Technical Analysis News

PHARMING GROUP

Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 382
Description

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Corporate Governance

Pharming Group N.V.’s ISS Governance QualityScore as of May 1, 2024 is 1. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 3; Compensation: 1.

PHARMING GROUP'S HOLDERS RANK

List of holders with stock participation in PHARMING GROUP.

Holder Rank Holder Shares Date Reported % Out Value